Advanced Hematologic Malignancies
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Advanced Hematologic Malignancies is an early-stage landscape with 0 programs across 16 companies. The most active players are Fate Therapeutics, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Takeda.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Fate Therapeutics
0 programs
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
0 programs
Takeda
0 programs
Institut de Recherches Internationales Servier
0 programs
Foghorn Therapeutics Inc.
0 programs
Kumquat Biosciences Inc.
0 programs
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
31
clinical trials
Clinical Trials
Trial Activity
31 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)